Saudi Arabia attracted $1.65bn in foreign direct investment (FDI) inflows in Q2 2023, the country’s Ministry of Economy and Planning said on Thursday.

That is 21.2% lower than the value recorded in the same period last year, according to Reuters.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

News about poor FDI inflows came after Saudi officials launched the Neom Investment Fund (NIF) on Tuesday (24 October), with the aim of pulling in investors to support the development of the planned city.

The government in Riyadh has been looking to attract more money from abroad to invest in different industry sectors and diversify away from fossil fuels.

Saudi Arabia continues to be Middle East and Africa’s (MEA) second most popular destination for FDI, just ahead of South Africa, a report published by GlobalData in May 2023 indicated.

Around 242 greenfield FDI projects were recorded in the country last year, 0.4% lower than in 2021. However, that still accounted for 10.0% of all FDI projects in the MEA region at the time.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Overall, the country came seventh when ranked against the number of FDI projects per million people in 2022 (6.96), below Israel and ahead of Kuwait.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact